Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.

Reich, K

Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. [electronic resource] - The British journal of dermatology Oct 2017 - 1014-1023 p. digital

Publication Type: Clinical Trial, Phase III; Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial

1365-2133

10.1111/bjd.15666 doi


Adult
Antibodies, Monoclonal, Humanized--administration & dosage
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Female
Humans
Injections, Subcutaneous
Male
Patient Reported Outcome Measures
Psoriasis--drug therapy
Treatment Outcome
Ustekinumab--administration & dosage